Search - tctmd.com

Displaying 81 - 100 of 127

Presentation TCT 2013

Two-Year Outcomes Following Implantation of 32mm and 38mm Platinum Chromium Everolimus Eluting Element Stents in Long Coronary Lesions

Presenter: Paul Teirstein, Gregg Stone, Ian Meredith, Robert Feldman, Joseph Dens, Abram Rabinowitz, Christophe Dubois, Dominic Allocco, Keith Dawkins

January 31, 2013

Presentation TCT 2013

Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow-up data...

Presenter: Peter Smits, A. J. van Boven, Mariano Valdes, Antonio Serra, Jean-Jacques Goy, V. Voudris, Ramiro Trillo, J. M. Vazquez, Peter den Heijer, Ton Slagboom, A.G. Vuillomenet

January 31, 2013

$Partial strut fracture in everolimus-eluting stents: An intravascular ultrasound study$

Presentation TCT 2013

Partial strut fracture in everolimus-eluting stents: An intravascular ultrasound study

Presenter: Shinji Inaba, Gary Mintz, Kyeong Yun, Tadayuki Yakushiji, Takehisa Shimizu, Giora Weisz, Martin Leon, Jeffrey Moses, Gregg Stone, Akiko Maehara

January 31, 2013

Presentation TCT 2013

Everolimus Eluting Stents Versus First Generation Drug Eluting Stents (Sirolimus or Paclitaxel) for Treatment of Drug-Eluting Stent In-Stent Restenosis

Presenter: Sachin Goel, Wael El-Mallah, Mobolaji Ige, Supriya Gupta, E Murat Tuzcu, Stephen Ellis, Samir Kapadia

January 31, 2013

Presentation TCT 2013

Cost Effectiveness Of Everolimus-Eluting Stents Compared To First Generation Drug-Eluting Stents In Contemporary Clinical Practice

Presenter: Robert Applegate, Matthew Sacrinty, Sanjay Gandhi, Michael Kutcher, Renato Santos, Timothy Smith, William Little

January 31, 2013

Presentation TCT 2013

Cost Effectiveness Of Everolimus-Eluting Stents Compared To Propensity Score Matched Bare Metal Stents In Contemporary Clinical Practice

Presenter: Robert Applegate, Matthew Sacrinty, Sanjay Gandhi, Michael Kutcher, Renato Santos, Timothy Smith, William Little

January 31, 2013

Presentation TCT 2013

Comparison of Zotarolimus-Eluting stents versus Everolimus –Eluting stents versus Sirolimus-Eluting and in Patients with Long Coronary Artery Lesions Assessed by Volumetric...

Presenter: Young-Rak Cho, Jung-Min Ahn, Soo-Jin Kang, Young-Hak Kim, Won-Jang Kim, Jong-Young Lee, Woo Seok Lee, Gyung-Min Park, Seung-Jung Park

January 31, 2013

Presentation TCT 2013

Comparison Of Long-term Outcomes With Everolimus-Eluting- and Sirolimus-Eluting Stents In Small Coronary Artery Disease

Presenter: Hironori Kitabata, Joshua Loh, Gabriel Sardi, Salem Badr, Danny Dvir, Israel Barbash, Rebecca Torguson, Kenneth Kent, Lowell Satler, William Suddath, Augusto Pichard, Ron Waksman

January 31, 2013

Presentation TCT 2013

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Presenter: Renato Valenti, Angela Migliorini, Guido Parodi, Ruben Vergara, Nazario Carrabba, Emilio Vincenzo Dovellini, David Antoniucci

January 31, 2013

Presentation TCT 2013

Abluminal- Only Coating Everolimus Eluting Coronary Stent Provides an Anti-inflammatory Vascular Effect Compared to Bare Metal Stents in the Familial Hypercholesterolemic Swine

Presenter: Armando Tellez, Elina Donskoy, Natalia Sushkova, Paul Seifert, Taylor Palmieri, William Rate, Samantha Stone, Michael Eppihimer, Greg Kaluza, Barbara Huibregtse, Keith Dawkins, Juan Granada

January 31, 2013

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 31, 2012

Presentation TCT 2012

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians

Presenter: Adam de Belder

October 26, 2012

News Conference News TCT 2012

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

October 26, 2012

Presentation TCT 2012

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

Presenter: Clemens von Birgelen

October 25, 2012

Presentation TCT 2012

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Ken Kozuma

October 25, 2012

Presentation TCT 2012

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

Presenter: Francesco Burzotta

October 25, 2012

Presentation TCT 2012

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Lisette Okkels Jensen

October 25, 2012

Presentation TCT 2012

EXAMINATION 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction

Presenter: Manel Sabate

October 25, 2012

Presentation TCT 2012

ISAR-LEFT MAIN 2: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents in Patients with Unprotected Left Main Disease

Presenter: Julinda Mehilli

October 24, 2012

News Conference News TCT 2012

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

October 24, 2012

Advertisement

Two-Year Outcomes Following Implantation of 32mm and 38mm Platinum Chromium Everolimus Eluting Element Stents in Long Coronary Lesions

Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow-up data...

Partial strut fracture in everolimus-eluting stents: An intravascular ultrasound study

Everolimus Eluting Stents Versus First Generation Drug Eluting Stents (Sirolimus or Paclitaxel) for Treatment of Drug-Eluting Stent In-Stent Restenosis

Cost Effectiveness Of Everolimus-Eluting Stents Compared To First Generation Drug-Eluting Stents In Contemporary Clinical Practice

Cost Effectiveness Of Everolimus-Eluting Stents Compared To Propensity Score Matched Bare Metal Stents In Contemporary Clinical Practice

Comparison of Zotarolimus-Eluting stents versus Everolimus –Eluting stents versus Sirolimus-Eluting and in Patients with Long Coronary Artery Lesions Assessed by Volumetric...

Comparison Of Long-term Outcomes With Everolimus-Eluting- and Sirolimus-Eluting Stents In Small Coronary Artery Disease

Comparison of Clopidogrel and Prasugrel in Patients with Unprotected Left main Disease Treated with Everolimus-Eluting Stents: Insight From the Florence Left Main-PCI Registry

Abluminal- Only Coating Everolimus Eluting Coronary Stent Provides an Anti-inflammatory Vascular Effect Compared to Bare Metal Stents in the Familial Hypercholesterolemic Swine

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians

No Excess Bleeding with EES vs. BMS in Octogenarians Despite Prolonged DAPT

TWENTE 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Long-Term Results of Bifurcation Stenting with Everolimus-eluting vs. Sirolimus-eluting Stents: The SEA-CORP BC Trials

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

EXAMINATION 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Bare Metal Stents in Patients with ST-Segment Elevation Myocardial Infarction

ISAR-LEFT MAIN 2: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents in Patients with Unprotected Left Main Disease

Experts Discuss Need for Development of Next-Generation DES, Insights from Pathology

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content